Table 1

Demographics and clinical characteristics of participants
Variable SLE patients Healthy controls
(n= 25) (n= 15)
IFN type I negative IFN type I positive
(n= 9) (n= 16)
Demographics
   Number of females, n (%) 9/9 (100%) 14/16 (88%) 15/15 (100%)
   Age (years) 41.3 ± 17.5 39.8 ± 15.7 41.0 ± 14.0
   Race, n (%)
   Caucasian 8/9 (89%) 7/16 (44%) 15/15 (100%)
   Black 0/9 (0) 8/16 (50%) 0/15 (0)
   Asian 0/9 (0) 0/16 (0) 0/15 (0)
   Mixed race 1/9 (11%) 1/16 (6%) 0/15 (0)
Clinical
   Disease duration (years) 12.1 ± 8.0 14.4 ± 11.3 -
   Mucocutaneous, n (%) 3/9 (33%) 10/16 (63%) -
   Arthritis, n (%) 7/9 (78%) 6/16 (38%) -
   Serositis, n (%) 1/9 (11%) 3/16 (19%) -
   Nephritis, n (%) 3/9 (33%) 9/16 (56%) -
   Neuropsychiatric, n (%) 1/9 (11%) 3/16 (19%) -
   Hematologic, n (%) 6/9 (67%) 12/16 (75%) -
Laboratory
   ANA positivity, n (%) 9/9 (100%) 16/16 (100%) -
   Anti-ds-DNA positivity, n (%) 5/9 (56%) 10/16 (63%) -
Treatment
   Hydroxychloroquine, n (%) 7/9 (78%) 11/16 (69%) -
   Corticosteroids, n (%) 5/9 (56%) 10/16 (63%) -
   Mycophenolate mofetil, n (%) 0/9 (0) 4/16 (25%) -
   Azathioprine, n (%) 2/9 (22%) 3/16 (19%) -
   Cyclophosphamide, n (%) 0/9 (0) 1/16 (6%) -

Values are the mean ± SD, median (25% quartile,75% quartile) or number (%) of patients, depending on whether the data are continuous or dichotomous, and whether the data are normally distributed or not.

Brkic et al.

Brkic et al. Arthritis Research & Therapy 2014 16:R62   doi:10.1186/ar4499

Open Data